This company listing is no longer active
BONES Stock Overview
BBS-Bioactive Bone Substitutes Oyj, a biomedical technology company, develops, manufactures, and commercializes bioactive medical devices and implants for orthopedic surgery in Finland.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
BBS-Bioactive Bone Substitutes Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €11.00 |
| 52 Week High | €30.50 |
| 52 Week Low | €10.00 |
| Beta | -0.081 |
| 1 Month Change | -34.91% |
| 3 Month Change | -15.38% |
| 1 Year Change | -53.78% |
| 3 Year Change | -86.75% |
| 5 Year Change | -75.56% |
| Change since IPO | -74.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| BONES | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -7.6% | -0.8% | -1.6% |
| 1Y | -53.8% | -5.1% | 7.8% |
Return vs Industry: BONES underperformed the Swedish Biotechs industry which returned 11.3% over the past year.
Return vs Market: BONES underperformed the Swedish Market which returned 2.1% over the past year.
Price Volatility
| BONES volatility | |
|---|---|
| BONES Average Weekly Movement | 18.0% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 12.8% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: BONES's share price has been volatile over the past 3 months.
Volatility Over Time: BONES's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 21 | Ilkka Kangasniemi | www.bbs-artebone.fi |
BBS-Bioactive Bone Substitutes Oyj, a biomedical technology company, develops, manufactures, and commercializes bioactive medical devices and implants for orthopedic surgery in Finland. The company offers ARTEBONE, an orthobiological product based on tricalcium phosphate and natural spectrum of bone proteins used primarily for the treatment of bone defects and healing problems in extremities, such as foot and ankle. BBS-Bioactive Bone Substitutes Plc was incorporated in 1991 and is headquartered in Oulu, Finland.
BBS-Bioactive Bone Substitutes Oyj Fundamentals Summary
| BONES fundamental statistics | |
|---|---|
| Market cap | kr124.17m |
| Earnings (TTM) | -kr34.54m |
| Revenue (TTM) | kr717.21k |
173.1x
P/S Ratio-3.6x
P/E RatioIs BONES overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BONES income statement (TTM) | |
|---|---|
| Revenue | €64.22k |
| Cost of Revenue | €29.95k |
| Gross Profit | €34.27k |
| Other Expenses | €3.13m |
| Earnings | -€3.09m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
Aug 25, 2023
| Earnings per share (EPS) | -0.32 |
| Gross Margin | 53.36% |
| Net Profit Margin | -4,815.48% |
| Debt/Equity Ratio | 132.8% |
How did BONES perform over the long term?
See historical performance and comparison